Literature DB >> 24293186

Roles of the PDZ domain-binding motif of the human papillomavirus type 16 E6 on the immortalization and differentiation of primary human foreskin keratinocytes.

Moonju Choi1, Sungjin Lee, Taekyu Choi, Choongho Lee.   

Abstract

A number of PDZ domain-containing proteins have been identified as binding partners for the oncoprotein E6 of the high-risk type human papillomaviruses (HPVs). These include hDlg, hScrib, MAGI1, MAGI2, and MAGI3, MUPP1, 14-3-3zeta, Na/H exchange regulatory factor 1, PTPN13, TIP-2/GIPC, Tip-1, and PATJ. The PDZ domain-binding motif (-X-T-X-V) at the carboxy terminus of E6 is essential for targeting PDZ proteins for proteasomal degradation. However, contribution of degradation of PDZ proteins by E6 to HPV-induced oncogenesis is still controversial. In order to clarify potential roles of molecular interactions between high-risk HPV E6 and one of best characterized PDZ proteins, hDlg in HPV-induced transformation, we used a retroviral infection system to overexpress HPV16 E7 gene alone or together with either HPV16 E6 wild type or E6 mutant gene lacking the PDZ domain-binding motif and investigated the effect of mutating the PDZ domain-binding motif of E6 on the immortalization and differentiation of human foreskin keratinocytes (HFKs) by the high-risk type HPV E6 and E7. Although the PDZ domain-binding motif of E6 was found to be required for the efficient growth of HFKs, it was not necessary for the E6 and E7-induced immortalization of HFKs. Furthermore, the overexpression of E6 and E7 neither induced degradation nor altered cellular localization of hDlg in undifferentiated or differentiated HFKs. These data indicate that the PDZ domain-binding motif of E6 contributes to the efficient cellular growth through mechanisms other than degradation and changes in the subcellular localizations of hDlg.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24293186     DOI: 10.1007/s11262-013-1017-9

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  46 in total

1.  Human papillomavirus type 8 E6 oncoprotein inhibits transcription of the PDZ protein syntenin-2.

Authors:  Daliborka Lazić; Martin Hufbauer; Paola Zigrino; Stephanie Buchholz; Siamaque Kazem; Mariet C W Feltkamp; Cornelia Mauch; Gertrud Steger; Herbert Pfister; Baki Akgül
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

2.  Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein.

Authors:  Alexandra Eichten; Matthew Westfall; Jennifer A Pietenpol; Karl Münger
Journal:  Virology       Date:  2002-03-30       Impact factor: 3.616

3.  Link of the unique oncogenic properties of adenovirus type 9 E4-ORF1 to a select interaction with the candidate tumor suppressor protein ZO-2.

Authors:  B A Glaunsinger; R S Weiss; S S Lee; R Javier
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

4.  Association of cottontail rabbit papillomavirus E6 oncoproteins with the hDlg/SAP97 tumor suppressor.

Authors:  Minjie Du; Xueli Fan; Toshihiko Hanada; Hua Gao; Mohini Lutchman; Janet L Brandsma; Athar H Chishti; Jason J Chen
Journal:  J Cell Biochem       Date:  2005-04-01       Impact factor: 4.429

5.  Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells.

Authors:  Y Liu; J J Chen; Q Gao; S Dalal; Y Hong; C P Mansur; V Band; E J Androphy
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase.

Authors:  D Pim; M Thomas; R Javier; D Gardiol; L Banks
Journal:  Oncogene       Date:  2000-02-10       Impact factor: 9.867

7.  PATJ, a tight junction-associated PDZ protein, is a novel degradation target of high-risk human papillomavirus E6 and the alternatively spliced isoform 18 E6.

Authors:  Carina H Storrs; Saul J Silverstein
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

Review 8.  Human papillomavirus infection and the primary and secondary prevention of cervical cancer.

Authors:  Douglas R Lowy; Diane Solomon; Allan Hildesheim; John T Schiller; Mark Schiffman
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

9.  Requirement of PDZ-containing proteins for cell cycle regulation and differentiation in the mouse lens epithelium.

Authors:  Minh M Nguyen; Marie L Nguyen; Georgina Caruana; Alan Bernstein; Paul F Lambert; Anne E Griep
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

10.  Comparison of p53 and the PDZ domain containing protein MAGI-3 regulation by the E6 protein from high-risk human papillomaviruses.

Authors:  Julia Ainsworth; Miranda Thomas; Lawrence Banks; Francois Coutlee; Greg Matlashewski
Journal:  Virol J       Date:  2008-06-02       Impact factor: 4.099

View more
  4 in total

1.  Human Papillomavirus E6 interaction with cellular PDZ domain proteins modulates YAP nuclear localization.

Authors:  Sydney Webb Strickland; Nicole Brimer; Charles Lyons; Scott B Vande Pol
Journal:  Virology       Date:  2018-01-12       Impact factor: 3.616

2.  Establishment of Immortalized Primary Human Foreskin Keratinocytes and Their Application to Toxicity Assessment and Three Dimensional Skin Culture Construction.

Authors:  Moonju Choi; Minkyung Park; Suhyon Lee; Jeong Woo Lee; Min Chul Cho; Minsoo Noh; Choongho Lee
Journal:  Biomol Ther (Seoul)       Date:  2017-05-01       Impact factor: 4.634

3.  Mitotic control of human papillomavirus genome-containing cells is regulated by the function of the PDZ-binding motif of the E6 oncoprotein.

Authors:  Elizabeth K Marsh; Craig P Delury; Nicholas J Davies; Christopher J Weston; Mohammed A L Miah; Lawrence Banks; Joanna L Parish; Martin R Higgs; Sally Roberts
Journal:  Oncotarget       Date:  2017-03-21

Review 4.  Viral Interactions with PDZ Domain-Containing Proteins-An Oncogenic Trait?

Authors:  Claire D James; Sally Roberts
Journal:  Pathogens       Date:  2016-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.